N B Henrikson

Summary

Affiliation: University of Washington
Country: USA

Publications

  1. ncbi Ancillary risk information and pharmacogenetic tests: social and policy implications
    N B Henrikson
    Institute for Public Health Genetics, School of Public Health and Community Medicine, University of Washington, Seattle, WA 98195, USA
    Pharmacogenomics J 8:85-9. 2008
  2. ncbi Does genomic risk information motivate people to change their behavior?
    Nora B Henrikson
    Group Health Cooperative, Center for Health Studies, 1730 Minor Ave, Suite 1600, Seattle, WA 98101, USA
    Genome Med 1:37. 2009
  3. ncbi "It's not like I can change my mind later": reversibility and decision timing in prostate cancer treatment decision-making
    Nora B Henrikson
    University of Washington School of Public Health and Community Medicine, Institute for Public Health Genetics, Seattle, WA 98195, USA
    Patient Educ Couns 77:302-7. 2009

Detail Information

Publications3

  1. ncbi Ancillary risk information and pharmacogenetic tests: social and policy implications
    N B Henrikson
    Institute for Public Health Genetics, School of Public Health and Community Medicine, University of Washington, Seattle, WA 98195, USA
    Pharmacogenomics J 8:85-9. 2008
    ..Implications will vary with each test but tests should be evaluated individually within a framework that outlines the potential implications of ancillary information...
  2. ncbi Does genomic risk information motivate people to change their behavior?
    Nora B Henrikson
    Group Health Cooperative, Center for Health Studies, 1730 Minor Ave, Suite 1600, Seattle, WA 98101, USA
    Genome Med 1:37. 2009
    ....
  3. ncbi "It's not like I can change my mind later": reversibility and decision timing in prostate cancer treatment decision-making
    Nora B Henrikson
    University of Washington School of Public Health and Community Medicine, Institute for Public Health Genetics, Seattle, WA 98195, USA
    Patient Educ Couns 77:302-7. 2009
    ..To explore whether reversibility, decision timing, and uncertainty are relevant to men deciding on treatment for localized prostate cancer (LPC)...